Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects

Journal of Geriatric Psychiatry and Neurology

Volumn 15, Issue 2, 2002, Pages 77-81

  Maxwell, Rae Ann ^a   Sweet, Robert A ^b   Mulsant, Benoit H ^a,b   Rosen, Jules ^b   Kirshner, Margaret A ^b   Kastango, Kari B ^b   Pollock, Bruce G ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PALIPERIDONE; RISPERIDONE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CORRELATION COEFFICIENT; CREATININE CLEARANCE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG METABOLISM; ELDERLY CARE; FEMALE; GERONTOPSYCHIATRY; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RADIOIMMUNOASSAY; STEADY STATE; URINALYSIS; AGING; MIDDLE AGED; URINE;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTIPSYCHOTIC AGENTS; CREATININE; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RADIOIMMUNOASSAY; RISPERIDONE;

EID: 0036014846     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198870201500205     Document Type: Article

References (22)

1. Psychoactive medication use in intermediate-care facility residents
2. A study of antipsychotic drug use in nursing homes: Epidemiologic evidence suggesting misuse
3. Antipsychotics in older patients: A safety perspective
4. Management of late-life psychosis
5. Comparison of four basic models of indirect pharmacodynamic responses
6. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study
7. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type
8. Troublesome and disruptive behaviors in dementia; relationships to diagnosis and disease severity
9. Neuroleptics in the elderly: Guidelines for monitoring
10. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone
11. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
12. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
13. Treating psychosis in Alzheimer's disease
14. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
15. Pharmacokinetics and drug disposition: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
16. Pharmacological profile of risperidone
17. The pharmacokinetics of risperidone in humans: A summary
18. Therapeutic dose: Serum level relationships of risperidone and active metabolite in a geriatric population
19. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man
20. New atypical antipsychotics: Experience and utility in the elderly
21. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology
22. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors